Skip to main content

Table 5 Defining, monitoring and reporting of harm in the PRIME trial

From: Collaborative care for the detection and management of depression among adults with hypertension in South Africa: study protocol for the PRIME-SA randomised controlled trial

Type of harm

Source and method of identification

Action(s) to mitigate harm to specific participants

Reporting frequency and to whom

Adverse events

 Positive response to ninth item of the PHQ-9: ‘Thoughts that you would be better off dead or of hurting yourself in some way’

Participant interviews (baseline, 6 month follow-up, 12 month follow-up).

Flag within electronic questionnaire prompting interviewer to act

Repeat question to reduce telescoping-type reporting errors.

If ≥ 8 days in last 2 weeks, immediate referral to clinic staff.

If between 1 and 7 days then written educational material given

6-monthly report to DSMB

6-monthly to IRB (with DSMB letter of recommendation)

 PHQ-9 score of ≥ 20 at 12 months suggesting persistent severe depression

Participant interviews (12-month follow-up).

Data report (monthly)

Summary forwarded to clinic together with recommendations for further treatment

6-monthly report to DSMB

6-monthly to IRB (with DSMB letter of recommendation)

 Blood pressure severely raised (≥ 180/110) placing participant at immediate risk of cardiovascular event

Participant interviews (baseline, 6-month follow-up, 12-month follow-up).

Flag within electronic questionnaire prompting interviewer to act

Immediate referral to clinic staff for review

6-monthly report to DSMB

6-monthly to IRB (with DSMB letter of recommendation)

 Raised blood pressure at follow-up representing undiagnosed or uncontrolled hypertension

Participant interviews (baseline, 6-month follow-up, 12-month follow-up).

Longitudinal patient record

Summary forwarded to clinic together with recommendations for further treatment

6-monthly report to DSMB

6-monthly to IRB (with DSMB letter of recommendation)

Serious adverse events

 Hospitalisation

Participant interviews (baseline, 6-month follow-up, 12-month follow-up).

Routinely collected hospitalisation data.

Data report (monthly).

No immediate action other than 6-monthly review by DSMB

6-monthly report to DSMB

6-monthly to IRB (with DSMB letter of recommendation)

 Death (excluding suicide)

Participant interviews (Loss to Follow-up Form).

National Population Register.

Data report (monthly)

No immediate action other than 6-monthly review by DSMB

6-monthly report to DSMB

6-monthly to IRB (with DSMB letter of recommendation)

 Death by suicide

Participant interviews (Loss to Follow-up Form).

National Population Register (providing we are able to access cause of death).

Data report (weekly)

Immediate notification of PI (LF) who will follow-up with fieldwork staff to confirm suicide and establish date of suicide

Notification of IRB, DSMB and NIMH within 7 days of knowledge of confirmed suicide

  1. DSMB Data and Safety Monitoring Board, IRB Institutional Review Board, PHQ-9 Patient Health Questionnaire-9, PI principal investigator